Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$9.9K-84.55%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Timothy Mark Dyer
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3
- Beta
- 1.96
- Country
- CH
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -150.54
Financials
Revenue
$9.9K-84.5%Net Income
$-1.74MEBITDA
$-617.7KFree Cash Flow
$-468.7KEPS (diluted)
$-1.20Shares Outstanding (diluted)
1.45M+1386.0%Operating Expenses
$652.4KCash & Debt
$767.3KReturn of Capital
$1.3KRevenue by Segment (annual)
$400.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $30.0K | $-6.73M | $-6.88 |
| 2024 | $404.1K | $7.06M | $8.40 |
| 2023 | $1.61M | $-10.56M | $-16.80 |
| 2022 | $1.42M | $-20.80M | $-55.20 |
| 2021 | $2.92M | $-15.35M | $-54.00 |
| 2020 | $3.61M | $-12.86M | $-57.60 |
| 2019 | $2.76M | $-14.78M | $-67.20 |
| 2018 | $6.04M | $-1.64M | $-8.47 |
| 2017 | $499.9K | $-3.28M | $-30.00 |
| 2016 | $17.3K | $-3.15M | $-33.60 |
| 2015 | $40.3K | $-4.20M | $-46.80 |
| 2014 | $85.4K | $-1.77M | $-21.60 |
| 2013 | $91.8K | $-14.46M | $-192.00 |
| 2012 | $121.1K | $-26.61M | $-403.20 |
Valuation
ADXNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
10-80.00%Social Signal Score
Mentions (7)
- Newsdefenseworld.net·6h ago·Negative
Addex (NASDAQ: ADXN) spin-out Neurosterix clears Phase 1, plans next stage What happened Addex Therapeutics Ltd. (NASDAQ: ADXN) said Neurosterix completed Phase 1 studies of NTX-253 and plans to move the drug into Phase 2. NTX-253 is a positive allosteric modulator of the muscarinic M4 receptor, and the program is being developed for schizophrenia. Addex said Neurosterix is its spin-out company and that Addex holds a
View source ↗ - Newsglobenewswire.com·2d ago·Neutral
…tes Phase 1 Clinical Studies of NTX-253 for Schizophrenia Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 8, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that its spin-out company, Neurosterix, in which Addex holds a 20% equity interest, has completed its Phase 1 clinical studies evaluating NTX-2…
View source ↗ - Newsglobenewswire.com·8d ago·Neutral
…chev, Head of Translational Science, Steps Down Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 2, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced the appointment of Jean-Philippe Rocher as Head of Pharmaceutical Development and member of the Executive Management.
View source ↗ - Newsseekingalpha.com·11d ago·Positive
Addex Therapeutics Ltd (ADXN) Q2 2026 Earnings Call Transcript Addex Therapeutics Ltd (ADXN) Q2 2026 Earnings Call Transcript
View source ↗ - Newsglobenewswire.com·12d ago·Neutral
Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 28, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its 2026 Half-Year and Second Quarter financial results and provided a corporate update.
View source ↗ - Newsglobenewswire.com·16d ago·Neutral
… Report 2026 Half-Year Financial Results and Host Conference Call on September 28, 2026 Geneva, Switzerland, September 24, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its 2026 Half-Year and Second Quarter financial results on September 28, 2026. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational S…
View source ↗ - Newsglobenewswire.com·45d ago·Neutral
… extends cash runway to the fourth quarter 2027 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 26, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it has raised gross proceeds of USD 2.8 million (CHF 2.2 million) through the sale of 437,869 ADSs representing 52,544,280 shares, through it's At the Mark…
View source ↗
Earnings
Mon, Nov 9(in 4 weeks)
Typical surprise -25.4% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Apr 30$-1.94 vs $-1.42miss
- Mon, Nov 10$-2.91 vs $-1.42miss
- Fri, Jun 20$-1.33 vs $-4.26beat
- Mon, Apr 7$-1.63 vs $-1.42miss
Estimates and results for ADXN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ADXN officers and directors.
No open-market trades in the recent filings. All 54 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
54 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ADXN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.